An AliveCor algorithm has identified people with high potassium levels from electrocardiogram (ECG) data. Limited prospective clinical testing suggests pairing the algorithm with AliveCor’s smartphone and Apple Watch-based ECGs could enable the remote, noninvasive monitoring of potassium levels.
Merck & Company and Tokyo-based Eisai Inc. have signed a strategic collaboration deal to develop and commercialize Lenvima (lenvatinib mesylate) with Merck’s anti-PD-1 drug Keytruda (pembrolizumab).
Medtec China 2018 is taking place on September 26–28 in Shanghai China. This year the scale of the show will grow by 10% reaching a new height since 2015; it is now at a scale making utilization of an entire hall possible to hold the show.
Four health systems — Intermountain Healthcare, Ascension, SSM Health and Trinity Health — and the U.S. Department of Veterans Affairs will launch a nonprofit generic drug company.
Finch Therapeutics, headquartered in Somerville, Massachusetts, closed on an oversubscribed Series B financing worth $36 million. Since the company’s launch, it has raised $77 million. Series B investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Gene therapy company MeiraGTx said the European Medicines Agency granted Priority Medicines (PRIME) designation to its candidate A002 for treatment of achromatopsia.
Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
Scientists have brought the prospect of spinal cord injuries being able to be treated with stem cells one step closer, after research in monkeys showed improvement post-stem cell graft.
Eli Lilly’s Verzenio has been given another green light in the US for breast cancer, significantly expanding the drug’s treatment scope.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.